NasdaqGS:NVAXBiotechs
Novavax’s Matrix-M Licensing Deal With Pfizer Could Be A Game Changer For Novavax (NVAX)
In January 2026, Novavax announced a non-exclusive, worldwide License and Option Agreement giving Pfizer access to its Matrix-M adjuvant technology for up to two infectious disease vaccine programs, along with an upfront US$30,000,000 payment.
This deal highlights how Novavax is positioning Matrix-M as a platform technology that larger vaccine manufacturers may incorporate across multiple disease areas.
Next, we’ll examine how this Matrix-M licensing agreement with Pfizer shapes Novavax’s...